Agnes Jaeger-Lansky

Learn More
Purpose: In this study, we tested the antitumor activity of the dual phosphoinositide 3-kinase (PI3K)/ mTOR inhibitor BEZ235 against gastric cancer in vitro and in vivo. Experimental Design: Gastric cancer cell lines (N87, MKN45, and MKN28) were incubated with BEZ235 and assessed for cell viability, cell cycle, and PI3K/mTOR target inhibition. In vivo,(More)
BACKGROUND Sclerostin is a soluble inhibitor of osteoblast function. Sclerostin is downregulated by the parathyroid hormone (PTH). Here, it was investigated whether sclerostin levels are influenced by intact (i) PTH and whether sclerostin is associated with bone turnover, microarchitecture and mass in dialysis patients. METHODS Seventy-six haemodialysis(More)
The vaccinations against human papilloma virus (HPV) are highly effective in preventing persistent infection. The level of knowledge about HPV and the consequences of an infection with this virus are low in the general population and in patients who suffer from HPV-associated diseases. We aimed to compare the level of knowledge about HPV and about the(More)
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Activation of the PI3K/mTOR pathway is a common event in gastric cancer and correlates with poor prognosis. PI3K/mTOR inhibition by the dual kinase inhibitor BEZ235 provides a novel and promising strategy for more effective treatment of gastric cancer(More)
  • 1